These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35345821)

  • 1. Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS.
    Kostka K; Duarte-Salles T; Prats-Uribe A; Sena AG; Pistillo A; Khalid S; Lai LYH; Golozar A; Alshammari TM; Dawoud DM; Nyberg F; Wilcox AB; Andryc A; Williams A; Ostropolets A; Areia C; Jung CY; Harle CA; Reich CG; Blacketer C; Morales DR; Dorr DA; Burn E; Roel E; Tan EH; Minty E; DeFalco F; de Maeztu G; Lipori G; Alghoul H; Zhu H; Thomas JA; Bian J; Park J; Martínez Roldán J; Posada JD; Banda JM; Horcajada JP; Kohler J; Shah K; Natarajan K; Lynch KE; Liu L; Schilling LM; Recalde M; Spotnitz M; Gong M; Matheny ME; Valveny N; Weiskopf NG; Shah N; Alser O; Casajust P; Park RW; Schuff R; Seager S; DuVall SL; You SC; Song S; Fernández-Bertolín S; Fortin S; Magoc T; Falconer T; Subbian V; Huser V; Ahmed WU; Carter W; Guan Y; Galvan Y; He X; Rijnbeek PR; Hripcsak G; Ryan PB; Suchard MA; Prieto-Alhambra D
    Clin Epidemiol; 2022; 14():369-384. PubMed ID: 35345821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS.
    Prieto-Alhambra D; Kostka K; Duarte-Salles T; Prats-Uribe A; Sena A; Pistillo A; Khalid S; Lai L; Golozar A; Alshammari TM; Dawoud D; Nyberg F; Wilcox A; Andryc A; Williams A; Ostropolets A; Areia C; Jung CY; Harle C; Reich C; Blacketer C; Morales D; Dorr DA; Burn E; Roel E; Tan EH; Minty E; DeFalco F; de Maeztu G; Lipori G; Alghoul H; Zhu H; Thomas J; Bian J; Park J; Roldán JM; Posada J; Banda JM; Horcajada JP; Kohler J; Shah K; Natarajan K; Lynch K; Liu L; Schilling L; Recalde M; Spotnitz M; Gong M; Matheny M; Valveny N; Weiskopf N; Shah N; Alser O; Casajust P; Park RW; Schuff R; Seager S; DuVall S; You SC; Song S; Fernández-Bertolín S; Fortin S; Magoc T; Falconer T; Subbian V; Huser V; Ahmed WU; Carter W; Guan Y; Galvan Y; He X; Rijnbeek P; Hripcsak G; Ryan P; Suchard M
    Res Sq; 2021 Mar; ():. PubMed ID: 33688639
    [No Abstract]   [Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries.
    Tan EH; Sena AG; Prats-Uribe A; You SC; Ahmed WU; Kostka K; Reich C; Duvall SL; Lynch KE; Matheny ME; Duarte-Salles T; Bertolin SF; Hripcsak G; Natarajan K; Falconer T; Spotnitz M; Ostropolets A; Blacketer C; Alshammari TM; Alghoul H; Alser O; Lane JCE; Dawoud DM; Shah K; Yang Y; Zhang L; Areia C; Golozar A; Recalde M; Casajust P; Jonnagaddala J; Subbian V; Vizcaya D; Lai LYH; Nyberg F; Morales DR; Posada JD; Shah NH; Gong M; Vivekanantham A; Abend A; Minty EP; Suchard M; Rijnbeek P; Ryan PB; Prieto-Alhambra D
    Rheumatology (Oxford); 2021 Oct; 60(SI):SI37-SI50. PubMed ID: 33725121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study.
    Duarte-Salles T; Vizcaya D; Pistillo A; Casajust P; Sena AG; Lai LYH; Prats-Uribe A; Ahmed WU; Alshammari TM; Alghoul H; Alser O; Burn E; You SC; Areia C; Blacketer C; DuVall S; Falconer T; Fernandez-Bertolin S; Fortin S; Golozar A; Gong M; Tan EH; Huser V; Iveli P; Morales DR; Nyberg F; Posada JD; Recalde M; Roel E; Schilling LM; Shah NH; Shah K; Suchard MA; Zhang L; Zhang Y; Williams AE; Reich CG; Hripcsak G; Rijnbeek P; Ryan P; Kostka K; Prieto-Alhambra D
    medRxiv; 2020 Oct; ():. PubMed ID: 33140074
    [No Abstract]   [Full Text] [Related]  

  • 7. Integrating real-world data from Brazil and Pakistan into the OMOP common data model and standardized health analytics framework to characterize COVID-19 in the Global South.
    Junior EPP; Normando P; Flores-Ortiz R; Afzal MU; Jamil MA; Bertolin SF; Oliveira VA; Martufi V; de Sousa F; Bashir A; Burn E; Ichihara MY; Barreto ML; Salles TD; Prieto-Alhambra D; Hafeez H; Khalid S
    J Am Med Inform Assoc; 2023 Mar; 30(4):643-655. PubMed ID: 36264262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study.
    Dixon BE; Wools-Kaloustian K; Fadel WF; Duszynski TJ; Yiannoutsos C; Halverson PK; Menachemi N
    medRxiv; 2020 Oct; ():. PubMed ID: 33106813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe.
    Moreno-Martos D; Verhamme K; Ostropolets A; Kostka K; Duarte-Sales T; Prieto-Alhambra D; Alshammari TM; Alghoul H; Ahmed WU; Blacketer C; DuVall S; Lai L; Matheny M; Nyberg F; Posada J; Rijnbeek P; Spotnitz M; Sena A; Shah N; Suchard M; Chan You S; Hripcsak G; Ryan P; Morales D
    Wellcome Open Res; 2022; 7():22. PubMed ID: 36845321
    [No Abstract]   [Full Text] [Related]  

  • 11. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience.
    Duarte-Salles T; Vizcaya D; Pistillo A; Casajust P; Sena AG; Lai LYH; Prats-Uribe A; Ahmed WU; Alshammari TM; Alghoul H; Alser O; Burn E; You SC; Areia C; Blacketer C; DuVall S; Falconer T; Fernandez-Bertolin S; Fortin S; Golozar A; Gong M; Tan EH; Huser V; Iveli P; Morales DR; Nyberg F; Posada JD; Recalde M; Roel E; Schilling LM; Shah NH; Shah K; Suchard MA; Zhang L; Zhang Y; Williams AE; Reich CG; Hripcsak G; Rijnbeek P; Ryan P; Kostka K; Prieto-Alhambra D
    Pediatrics; 2021 Sep; 148(3):. PubMed ID: 34049958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational study.
    Sudre CH; Keshet A; Graham MS; Joshi AD; Shilo S; Rossman H; Murray B; Molteni E; Klaser K; Canas LD; Antonelli M; Nguyen LH; Drew DA; Modat M; Pujol JC; Ganesh S; Wolf J; Meir T; Chan AT; Steves CJ; Spector TD; Brownstein JS; Segal E; Ourselin S; Astley CM
    Lancet Digit Health; 2021 Sep; 3(9):e577-e586. PubMed ID: 34305035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe.
    Morales DR; Ostropolets A; Lai L; Sena A; Duvall S; Suchard M; Verhamme K; Rjinbeek P; Posada J; Ahmed W; Alshammary T; Alghoul H; Alser O; Areia C; Blacketer C; Burn E; Casajust P; You SC; Dawoud D; Golozar A; Gong M; Jonnagaddala J; Lynch K; Matheny M; Minty E; Nyberg F; Uribe A; Recalde M; Reich C; Scheumie M; Shah K; Shah N; Schilling L; Vizcaya D; Zhang L; Hripcsak G; Ryan P; Prieto-Alhambra D; Durate-Salles T; Kostka K
    J Asthma; 2023 Jan; 60(1):76-86. PubMed ID: 35012410
    [No Abstract]   [Full Text] [Related]  

  • 16. Authors' response: Occupation and SARS-CoV-2 infection risk among workers during the first pandemic wave in Germany: potential for bias.
    Reuter M; Rigó M; Formazin M; Liebers F; Latza U; Castell S; Jöckel KH; Greiser KH; Michels KB; Krause G; Albrecht S; Öztürk I; Kuss O; Berger K; Lampl BMJ; Leitzmann M; Zeeb H; Starke KR; Schipf S; Meinke-Franze C; Ahrens W; Seidler A; Klee B; Pischon T; Andreas Deckert AD; Schmidt B; Mikolajczyk R; Karch A; Bohn B; Brenner H; Holleczek B; Dragano N
    Scand J Work Environ Health; 2022 Sep; 48(7):588-590. PubMed ID: 36153787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
    Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
    Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological Issues in Using a Common Data Model of COVID-19 Vaccine Uptake and Important Adverse Events of Interest: Feasibility Study of Data and Connectivity COVID-19 Vaccines Pharmacovigilance in the United Kingdom.
    Delanerolle G; Williams R; Stipancic A; Byford R; Forbes A; Tsang RSM; Anand SN; Bradley D; Murphy S; Akbari A; Bedston S; Lyons RA; Owen R; Torabi F; Beggs J; Chuter A; Balharry D; Joy M; Sheikh A; Hobbs FDR; de Lusignan S
    JMIR Form Res; 2022 Aug; 6(8):e37821. PubMed ID: 35786634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study.
    Xiong S; Liu L; Lin F; Shi J; Han L; Liu H; He L; Jiang Q; Wang Z; Fu W; Li Z; Lu Q; Chen Z; Ding S
    BMC Infect Dis; 2020 Oct; 20(1):787. PubMed ID: 33092539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.